首站-论文投稿智能助手
典型文献
Paris saponin Ⅶ,a Hippo pathway activator,induces autophagy and exhibits therapeutic potential against human breast cancer cells
文献摘要:
Dysregulation of the Hippo signaling pathway seen in many types of cancer is usually associated with a poor prognosis.Paris saponin Ⅶ(PSⅦ)is a steroid saponin isolated from traditional Chinese herbs with therapeutic action against various human cancers.In this study we investigated the effects of PSⅦ on human breast cancer(BC)cells and its anticancer mechanisms.We showed that PSⅦ concentration-dependently inhibited the proliferation of MDA-MB-231,MDA-MB-436 and MCF-7 BC cell lines with IC50 values of 3.16,3.45,and 2.86 μM,respectively,and suppressed their colony formation.PSⅦ(1.2-1.8 μM)induced caspase-dependent apoptosis in the BC cell lines.PSⅦ treatment also induced autophagy and promoted autophagic flux in the BC cell lines.PSⅦ treatment decreased the expression and nuclear translocation of Yes-associated protein(YAP),a downstream transcriptional effector in the Hippo signaling pathway;overexpression of YAP markedly attenuated PSⅦ-induced autophagy.PSⅦ-induced,YAP-mediated autophagy was associated with increased active form of LATS1,an upstream effector of YAP.The activation of LATS1 was involved the participation of multiple proteins(including MST2,MOB1,and LATS1 itself)in an MST2-dependent sequential activation cascade.We further revealed that PSⅦ promoted the binding of LATS1 with MST2 and MOB1,and activated LATS1 in the BC cell lines.Molecular docking showed that PSⅦ directly bound to the MST2-MOB1-LATS1 ternary complex.Microscale thermophoresis analysis and drug affinity responsive targeting stability assay confirmed the high affinity between PSⅦ and the MST2-MOB1-LATS1 ternary complex.In mice bearing MDA-MB-231 cell xenograft,administration of PSⅦ(1.5 mg/kg,ip,4 times/week,for 4 weeks)significantly suppressed the tumor growth with increased pLATS1,LC3-Ⅱ and Beclin 1 levels and decreased YAP,p62 and Ki67 levels in the tumor tissue.Overall,this study demonstrates that PSⅦ is a novel and direct Hippo activator that has great potential in the treatment of BC.
文献关键词:
作者姓名:
Yu-chen Xiang;Peng Peng;Xue-wen Liu;Xin Jin;Jie Shen;Te Zhang;Liang Zhang;Fang Wan;Yu-liang Ren;Qing-qing Yu;Hu-zi Zhao;Yuan Si;Ying Liu
作者机构:
Laboratory of Molecular Target Therapy of Cancer,Institute of Basic Medical Sciences,Hubei University of Medicine,Shiyan 442000,China;Hubei Key Laboratory of Wudang Local Chinese Medicine Research,Hubei University of Medicine,Shiyan 442000,China;Hubei Key Laboratory of Embryonic Stem Cell Research,Hubei University of Medicine,Shiyan 442000,China;Laboratory of Molecular Target Therapy of Cancer,Biomedical Research Institute,Hubei University of Medicine,Shiyan 442000,China
引用格式:
[1]Yu-chen Xiang;Peng Peng;Xue-wen Liu;Xin Jin;Jie Shen;Te Zhang;Liang Zhang;Fang Wan;Yu-liang Ren;Qing-qing Yu;Hu-zi Zhao;Yuan Si;Ying Liu-.Paris saponin Ⅶ,a Hippo pathway activator,induces autophagy and exhibits therapeutic potential against human breast cancer cells)[J].中国药理学报(英文版),2022(06):1568-1580
A类:
pLATS1
B类:
Paris,saponin,Hippo,pathway,activator,induces,autophagy,exhibits,therapeutic,potential,against,human,breast,cells,Dysregulation,signaling,seen,many,types,usually,associated,poor,prognosis,PS,steroid,isolated,from,traditional,Chinese,herbs,action,various,cancers,In,this,study,investigated,effects,BC,anticancer,mechanisms,We,showed,that,concentration,dependently,inhibited,proliferation,MB,MCF,lines,IC50,values,respectively,suppressed,their,colony,formation,induced,caspase,apoptosis,treatment,also,promoted,autophagic,flux,decreased,nuclear,translocation,Yes,YAP,downstream,transcriptional,effector,overexpression,markedly,attenuated,mediated,was,increased,active,upstream,activation,involved,participation,multiple,proteins,including,MST2,MOB1,itself,sequential,cascade,further,revealed,binding,activated,Molecular,docking,directly,bound,ternary,complex,Microscale,thermophoresis,analysis,drug,affinity,responsive,targeting,stability,assay,confirmed,high,between,mice,bearing,xenograft,administration,times,weeks,significantly,tumor,growth,LC3,Beclin,levels,p62,Ki67,tissue,Overall,demonstrates,novel,has,great
AB值:
0.495788
相似文献
N6?methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance
Xian Lin;Feng Wang;Jian Chen;Jing Liu;Yi?Bin Lin;Li Li;Chuan?Ben Chen;Qin Xu-Departments of Gynecology,Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,Fujian Medical University,Fuzhou 350014,China;Department of Radiation Oncology,Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,Fujian Medical University,Fuzhou 350014,China;Shenzhen Key Laboratory of Immunity and Inflammatory Diseases,Peking University Shenzhen Hospital,Shenzhen Peking University?the Hong Kong University of Science and Technology Medical Center,Shenzhen 518036,Guangdong,China;Outpatient Department,Fujian Hospital of People's Armed Police,Fujian Medical University,Fuzhou 350014,China
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
Tingting Feng;Jing Wang;Kai Cheng;Qiqi Lu;Ru Zhao;Shiguan Wang;Qingyun Zhang;Luna Ge;Jihong Pan;Guanhua Song;Lin Wang-Department of Pathology,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Department of Pathology,The Fourth People's Hospital of Jinan,Jinan 250031,China;Department of PET-CT,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250002,China;The Second Hospital,Cheeloo College of Medicine,Shandong University Medical School,Jinan 250012,China;Biomedical Sciences College&Shandong Medicinal Biotechnology Centre,Key Lab for Biotech-Drugs of National Health Commission,Key Lab for Rare&Uncommon Diseases of Shandong Province,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Biochemistry and Molecular Biology,Shandong University School of Basic Medical Sciences,Jinan 250012,China;Institute of Basic Medicine,Shandong Academy of Medical Sciences,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Oncology,The First Affiliated Hospital of Shandong First Medical University,Jinan 250014,China
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
Bradykinin postconditioning protects rat hippocampal neurons after restoration of spontaneous circulation following cardiac arrest via activation of the AMPK/mTOR signaling pathway
Shi-Rong Lin;Qing-Ming Lin;Yu-Jia Lin;Xin Qian;Xiao-Ping Wang;Zheng Gong;Feng Chen;Bin Song-Provincial College of Clinical Medicine,Fujian Medical University,Fuzhou,Fujian Province,China;Department of Emergency,Fujian Provincial Hospital South Branch,Fuzhou,Fujian Province,China;Department of Emergency,Fujian Provincial Hospital,Fuzhou,Fujian Province,China;Fujian Emergency Medical Center,Fuzhou,Fujian Province,China;Fujian Provincial Key Laboratory of Emergency Medicine,Fuzhou,Fujian Province,China;Department of Human Anatomy,School of Basic Medical Sciences,Fujian Medical University, Fuzhou,Fujian Province,China;Key Laboratory of Brain Aging and Neurodegenerative Diseases of Fujian Province,Fuzhou,Fujian Province,China;Laboratory of Clinical Applied Anatomy,Fujian Medical University,Fuzhou,Fujian Province,China
Paired box 5 increases the chemosensitivity of esophageal squamous cell cancer cells by promoting p53 signaling activity
Zhang Weiwei;Yan Wenji;Qian Niansong;Han Quanli;Zhang Weitao;Dai Guanghai-Chinese People’s Liberation Army Medical School, Beijing 100853, China;Department of the Third Health Care, The Second Medical Center, Chinese People’s Liberation Army General Hospital, Beijing 100853, China;Department of Oncology, The First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing 100853, China;Department of Oncology, The Hainan Medical Center, Chinese People’s Liberation Army General Hospital, Sanya 572022, China;Cancer Center, Beijing Tongren Hospital Affiliated to Capital Medical University, Economic and Technological Development Zone, Beijing 100176, China
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou;Libin Zou;Hangyu Liao;Junqi Luo;Taowei Yang;Jun Wu;Wenbin Chen;Kaihui Wu;Shengren Cen;Daojun Lv;Fangpeng Shu;Yu Yang;Chun Li;Bingkun Li;Xiangming Mao-Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Second Department of Hepatobiliary Surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Department of Urology,Minimally Invasive Surgery Center,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Urology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Urology,Peking University Shenzhen Hospital,Shenzhen 518036,China;Nursing Department,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models
Ming Ji;Dongjie Wang;Songwen Lin;Chunyang Wang;Ling Li;Zhihui Zhang;Jing Jin;Deyu Wu;Yi Dong;Heng Xu;Duo Lu;Xiaoguang Chen-State Key Laboratory of Bioactive Substances and Functions of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。